Alpha Cognition Inc. ACOG
Alpha Cognition Inc. (Nasdaq: ACOG) is a CNS/neurology/psychiatry drug developer. Its lead program, ZUNVEYL (benzgalantamine), is in Pre-clinical for Mild to moderate dementia of the Alzheimer's type.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| ZUNVEYL (delayed-release oral tablet) | Mild to moderate Alzheimer's disease | small molecule | Approved |
| ZUNVEYL + memantine combination | Moderate-to-severe Alzheimer's disease | small molecule | Pre-clinical |
| ALPHA-1062 sublingual formulation (ALPHA-1062IN) | Mild-moderate Alzheimer's disease / dysphagia | small molecule | Pre-clinical |
| ALPHA-1062 sublingual | Cognitive impairment with mild traumatic brain injury | small molecule | Pre-clinical |
| ALPHA-0602 / 0702 / 0802 (Progranulin) | ALS, SMA | gene therapy | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.